Table 1.
Demographic and outcome of 20 patients with Crohn’s disease referred for kidney biopsy after twelve-month treatments in detail
| Patient | Sex | Age at kidney biopsy (yr) | Age at CD diagnosis (yr) | Renal pathology | CD treatment | Renal treatment | Outcome of CD | Outcome of proteinuria | Outcome of hematuria |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 45 | 43 | IgA nephropathy | Thalidomide | RAS inhibitors, steroids intravenously | Remission | CR | CR |
| 2 | M | 37 | 36 | IgA nephropathy | Thalidomide | - | ND | ND | ND |
| 3 | F | 17 | 15 | IgA nephropathy | Methylprednisolone tablets, methotrexate | - | Remission | CR | PR |
| 4 | M | 36 | 22 | IgA nephropathy | Infliximab, azathioprine | - | Remission | CR | R |
| 5 | M | 31 | 21 | IgA nephropathy | Azathioprine, enteral nutrition | - | Remission | CR | CR |
| 6 | F | 28 | 27 | IgA nephropathy | Infliximab | Pozzi regimen | ND | ND | ND |
| 7 | F | 16 | 18 | Minimal change disease | Methylprednisolone tablets and azathioprine | Steroids intravenously | Remission | CR | CR |
| 8 | M | 34 | 26 | Minimal change disease | Enteral nutrition | RAS inhibitors | Response | CR | PR |
| 9 | F | 19 | 18 | Thin-basement-membrane nephropathy | Infliximab, azathioprine | - | Remission | CR | PR |
| 10 | F | 38 | 37 | IgA nephropathy | Thalidomide, enteral nutrition | - | Remission | CR | R |
| 11 | F | 52 | 51 | Acute interstitial nephritis | Thalidomide | Steroids intravenously | Remission | CR | CR |
| 12 | M | 23 | 22 | non-IgA mesangial proliferative nephritis | Infliximab, azathioprine | - | Response | CR | R |
| 13 | F | 25 | 24 | IgA nephropathy | Infliximab | Pozzi regimen | Remission | CR | CR |
| 14 | M | 68 | 55 | IgA nephropathy | Enteral nutrition | Prednisone acetate tablets, mycophenolate mofetil | Remission | R | PR |
| 15 | M | 34 | 32 | IgA nephropathy | Thalidomide | RAS inhibitors | Relapse | CR | CR |
| 16 | M | 20 | 17 | IgA nephropathy | Infliximab, azathioprine | Pozzi regimen | Remission | R | PR |
| 17 | F | 65 | 42 | Granulomatous interstitial nephritis | Infliximab | Prednisone acetate tablets | Remission | CR | CR |
| 18 | F | 31 | 24 | IgA nephropathy | Mesalamine, azathioprine | RAS inhibitors | ND | ND | ND |
| 19 | M | 24 | 19 | IgA nephropathy | Infliximab, azathioprine | RAS inhibitors | Remission | CR | PR |
| 20 | M | 27 | 25 | IgA nephropathy | Infliximab, azathioprine | - | Remission | CR | CR |
M Male, F Female, ND No data. “-” referred to without any treatments
Outcome of CD: remission was defined as CDAI change from ≥ 150 or < 150 to < 150. Response was considered to be present if CDAI decreased by 70 or more but remained ≥ 150. Relapse was defined as CDAI change from < 150 to ≥ 150 or increased by 70 or more but remained ≥ 150
Outcome of proteinuria or hematuria: complete remission (CR) was defined as urinalysis change from negative, trace or ≥ 1 + to negative or trace. Partial remission (PR) was considered to be present if urinalysis decreased more than one stage but remained ≥ 1 + . Relapse (R) was defined as urinalysis change from negative or trace to ≥ 1 + or increased more than one stage but remained ≥ 1 +